Linc00423 As A Tumor Suppressor In Retroperitoneal Liposarcoma Via Activing Mapk Signaling Pathway Through Destabilizing Of Nfatc3

Yong Zhang,Hanxing Tong,Junyi He,Yebo Shao,Xi Guo,Rongyuan Zhuang,Jue Yang,Ju Liu,Yuqin Ding,Wenshuai Liu,Weiqi Lu,Yuhong Zhou

DOI: https://doi.org/10.1038/s41419-019-1658-2

2019-01-01

Abstract:Unraveling the noncoding RNA expression networks governing cancer initiation and development is essential while remains largely uncompleted in retroperitoneal liposarcoma (RLS). Through RNA-seq technologies and computational biology, deregulated long noncoding RNAs (lncRNAs) are being identified and reveal that lncRNAs are implicated in serial steps of RLS development. High-throughput sequencing with computational methods for assembling the transcriptome of five paired RLS patient's tissues. We found that long intergenic noncoding RNA 423 (linc00423) was downregulated in RLS tissues. Gain-of-function assays revealed that overexpressed linc00423 obviously inhibited RLS cell growth in vitro and in vivo. Additionally, RNA sequence, RNA-pulldown and RIP assays evidenced that linc00423 involved in MAPK signaling pathway via destabilizing of nuclear factor of activated T-cells 3 (NFATC3). Summing up, our findings demonstrated that linc00423 acted as the tumor suppressor in RLS cells through regulating the protein level of NFATC3 at a post-transcriptional level and negatively regulated the MAPK signaling pathway at a transcriptional level. Linc00423 might serve as a candidate prognostic biomarker and a target for novel therapies of RLS patients.